Work

302 Mitigating exhaustion in ex-vivo expanded tumor-associated antigen specific T cells

Year: 2026
Type: conference-paper
Abstract: Background Pediatric patients with relapsed/refractory solid tumors have few effective therapeutic options, despite advancement of targeted therapies that have transformed the treatment paradigm and outcomes for certain pediatric cancers. 1–5 Tumor-associated antigen-specific T cells (TAA-Ts) have shown promising results in early-phase trials, however clinical responses have been limited to disease stabilization.6 7 TAA-T manufacturing requires multiple stimulations with the target antigen, which is known to induce exhaustion and anergy.8 Patient-derived TAA-Ts also carry the complication of prior chemotherapy and antigen exposure in vivo.9 I hypothesize that patient-derived TAA-Ts will exhibit a more exhausted profile compared to healthy donor-derived products, with high expression of PD-L1 independent of donor, and that PD-L1 inhibition during TAA-T manufacturing will mitigate exhaustion for enhanced expansion, specificity, and cytotoxicity. This project will further our understanding of the cellular mechanisms that underly TAA-T function and influence their effectiveness in-vivo through interactions with the tumor microenvironment. This research will advance the manufacturing and application of a more potent TAA-T product that can be translated to a broad patient population.Methods TAA-Ts generated from patients and healthy donors will be characterized by flow cytometry for expression of PD-L1, PD-1, CTLA-1, TIM-3, LAG3, and CD39, correlated to expansion, cytokine production, and cytotoxicity in vitro. Products will be manufactured according to standardized methods, with the addition of a PD-L1 inhibitor at prescribed concentrations, and characterized via antigen specificity (IFNy ELISpot, intracellular cytokine staining), expansion (normalized cell counts), exhaustion (flow cytometry), and cytolytic activity (in vitro cytotoxicity assays/tumor rechallenge).Results Healthy donor-derived TAA-Ts demonstrate elevated levels of PD-L1 (median 61.9%, range 17–81.4%), CTLA-4 (69.8%, 38.6–81.7%), LAG-3 (62.9%, 17–67.4%), and TIGIT (60.4%, 19.9–75.6%) with antigen stimulation during ex-vivo expansion. We observed decreased expression of each marker (PD-L1 53% vs. 4%; CTLA-4 63% vs. 34%; LAG-3 49% vs. 30%; TIGIT 52% vs. 22%) with PD-L1 inhibition during manufacturing ( figure 1), but no significant difference in ex-vivo expansion, specificity, or cytotoxicity (figure 2).Conclusions PDL-1 inhibition alone during manufacturing of TAA-T cells from healthy donors does not clearly enhance ex-vivo expansion, specificity, or cytotoxicity. High expression of CD-39 (45–55%), a critical enzyme in the immunosuppressive adenosine pathway, was observed in all TAA-T products, independent of PDL-1 inhibition. 10–12 Future directions include repeat cytotoxicity assays including tumor rechallenge to characterize functional exhaustion and investigation of the role of adenosine in manufacture and function of TAA-T products.Acknowledgements Thanks to the entire CCIR team, especially everyone that has helped train me in lab work, given me tips along the way, and generously donated supplies and reagents. Thanks to my mentors for their endless patience and wisdom. Thanks to my patients who serve as a source of constant inspiration and fulfillment.References Smith AM, et al. Declining childhood and adolescent cancer mortality. Cancer 2014;120:2497–2506.Smith AM, et al. Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol. 2010;28:2625–2634.Sengsayadeth S, et al. Overview of approved CAR-T therapies, ongoing clinical trials, and its impact on clinical practice. eJHaem 2022;3(Suppl 1):6–10.Maude LS, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439–448.Mceachron AT, Helman JL. Recent advances in pediatric cancer research. Cancer Res. 2021;81:5783–5799.Kinoshita H, et al. Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT. Blood Adv. 2022;6:2520–2534.Hont BA, et al. Immunotherapy of relapsed and refractory solid tumors with ex vivo expanded multi-tumor associated antigen specific cytotoxic T lymphocytes: a phase I study. J Clin Oncol. 2019;37:2349–2359.Jiang W, et al. Exhausted CD8+ T cells in the tumor immune microenvironment: New pathways to therapy. Front Immunol. 2021;11.Hont BA, et al. The generation and application of antigen-specific T cell therapies for cancer and viral-associated disease. Mol Ther. 2022;30:2130–2152.A D, B A, J S. On the mechanism of anti-CD39 immune checkpoint therapy. J Immunother Cancer. 2020;8:e000186corr1.Vijayan D, et al. Erratum: targeting immunosuppressive adenosine in cancer. Nat Rev Cancer. 2017;17:765.Moesta AK, Li XY, Smyth MJ. Targeting CD39 in cancer. Nat Rev Immunol. 2020;20:739–755.Abstract 302 Figure 1Changes in surface marker expression are seen with PDL-1 inhibitionAbstract 302 Figure 2No clear increase in cytotoxicity is observed with PDL-1 inhibition during manufacturing
Institution: Children's National
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
Estimated APC paid: $2,490
OpenAlex ID: W7225169466
FWCI:
Cites: 11
Cited by:
Related to: 10